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Abstract
Background: Alzheimer’s disease (AD) involves loss of cholinergic neurons and Tau protein hyper-phosphorylation. Here, we
report that overexpression of an N-terminally extended ‘‘synaptic’’ acetylcholinesterase variant, N-AChE-S is causally
involved in both these phenomena.
Methodology and Principal Findings: In transfected primary brain cultures, N-AChE-S induced cell death, morphological
impairments and caspase 3 activation. Rapid internalization of fluorescently labeled fasciculin-2 to N-AChE-S transfected
cells indicated membranal localization. In cultured cell lines, N-AChE-S transfection activated the Tau kinase GSK3, induced
Tau hyper-phosphorylation and caused apoptosis. N-AChE-S-induced cell death was suppressible by inhibiting GSK3 or
caspases, by enforced overexpression of the anti-apoptotic Bcl2 proteins, or by AChE inhibition or silencing. Moreover,
inherent N-AChE-S was upregulated by stressors inducing protein misfolding and calcium imbalances, both characteristic of
AD; and in cortical tissues from AD patients, N-AChE-S overexpression coincides with Tau hyper-phosphorylation.
Conclusions: Together, these findings attribute an apoptogenic role to N-AChE-S and outline a potential value to AChE
inhibitor therapeutics in early AD.
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Introduction
In Alzheimer’s disease (AD), premature death of cholinergic
neurons is associated with accumulation of neurofibrillary tangles,
constituting of hyper-phosphorylated Tau [1]. The cholinergic
hypothesis attributes the cognitive impairments in AD to the loss of
cholinergic functions [2]. Accordingly, acetylcholinesterase
(AChE) inhibitors serve to ameliorate symptoms by prolonging
acetylcholine (ACh) availability [3]. Some argue for attenuation of
the disease process under treatment with AChE inhibitors [4,5];
others develop alternative AD therapeutics, including inhibitors of
the Tau kinase, Glycogen Synthase Kinase 3 (GSK3) [6,7], or of
other key proteins of the apoptotic pathway, but it is still unclear if
these different approaches reflect a single targeted cascade and if
so, what triggers this cascade.
Apoptotic cell death leads to cortical shrinkage in AD brains,
accompanied by massive loss of cholinergic neurons, which
express considerably more AChE than other neuron types [8].
Recent reports demonstrated AChE accumulation in apoptotic
cells, and AChE inhibition and general silencing were found to
prevent apoptosome formation and cell death [9,10]. Such cell
death may occur through activation of the endoplasmic reticulum
(ER), mitochondrial stress and/or cell surface death receptors
[11,12]. However, these reports raised a new question: how do
AChE-expressing neurons survive? Importantly, AChE is not one
but several variants, induced by alternate promoter usage and
alternative splicing [13]. It occurred to us that some, but not all,
AChE variants, may lead to the neuronal cell death which occurs
in AD. To challenge this theory, we studied AChE expression in
the AD cortex, tested the effects of aberrant AChE gene expression
in cultured cells, explored the molecular mechanism(s) involved by
manipulating both AChE and key apoptotic proteins, and
searched for pharmacological means capable of mitigating the
observed apoptotic effects.
Results
N-AChE-S expression induces caspase-mediated cell
death
Overexpression of two short (AChE-S, AChE-R) and two N-
terminally extended AChE variants(N-AChE-S, N-AChE-R) [13]
(Fig 1A), was induced by transient transfection of mouse primary
cortical cells, HEK 293 embryonic kidney cells, U87MG
glioblastoma, T84 lung epithel and CHO hamster ovary cells. In
primary cortical cells expressing N-AChE-S, this invariably caused
apoptosis, observed as increased TUNEL labeling and caspase 3
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3108activation (Fig 1B and C, respectively). Surviving cortical cells
transfected with N-AChE-S showed similar cell body size to those
expressing the other variants; however, they extended fewer and
shorter processes from the cell body than cells expressing any of
the other variants, indicating ill health for transfected surviving
cells (Fig 1D). Importantly, no other tested AChE variant exerted
Figure 1. N-AChE-S induced apoptosis in primary cortical cells. A. AChE mRNA transcripts. Upper scheme: The AChE gene structure.
Alternate ATG codons are indicated. Lower scheme: corresponding transcripts with respective open reading frames noted (amino acids). B. Primary
cortical cells. Upper micrographs: N-AChE-S and Cherry cells co-transfected with (red) were TUNEL labeled (green). Lower micrographs: Red labeling
as above, green label shows active caspase-3. C. Effects of AChE variants. Primary cortical cells 24 hr after co-transfection with Cherry and different
AChE variants co-transfected with Cherry show non apoptotic cells with different characteristics. N-AChE-S transfections confers shrunk features. D.
Shown are cell body diameters, percent of apoptotic cortical cells, No. of ramifications extended from cell bodies, average neurites length, and
percent of cells labeled with caspase 3 activated antibody for cells transfected with (from left to right) AChE-R, AChE-S, N-AChE-R and N-AChE-S (red
columns). Note N-AChE-S induced changes(*p=0.001,**p=0.0001 Student’s t test).
doi:10.1371/journal.pone.0003108.g001
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indirect effects of secreted AChE or other proteins, by demon-
strating that pre-conditioned medium, removed 24 hr after
transfection and added to non-transfected cells, caused no
apoptotic effect (Fig 2A and Table S1). Together, this attributed
the caused cell death to intracellular overexpression of N-AChE-S.
Moreover, N-AChE-S overexpressing cells showed concurrent
increases in both activated caspase 3 and 9 (Fig 2B) and the
Figure 2. N-AChE-S induces caspase-mediated cell death. A. N-AChE-S mediated apoptosis. TUNEL analysis 24 hr post-transfection in U87MG
cells transfected with AChE variants or an ‘‘empty’’ plasmid, compared with non-transfected cells incubated with pre-conditioned medium
(*p=0.001, Student’s t test). B. Caspase immunostaining. N-AChE-S-associated increases in activated caspase 3 and 9 and N-AChE-R-associated
reduction in caspase 3 in U87MG cells (*p=0.04, **p=0.004, ***p=0.0003 Student’s t test). C. Caspase activation reporter. N-AChE-S was co-injected
with GFP-NLS vector equipped with NES sequence and a caspase-cleavable DEVD motif. Caspase activation yields nuclear GFP translocation. D.
Microinjection-induced caspase-mediated cell death. Micrographs: 3T3 cells co-injected with an ‘‘empty’’ plasmid and GFP-NES/NLS (top micrograph)
showed cytoplasmic GFP, whereas N-AChE-S co-injected cells (bottom micrograph) showed nuclear fluorescence (columns). Shown are
representative cells, out of N=70, p,10
27 Student’s t test. E. Within 24 hr from injection, cells expressing N-AChE-S acquired nuclei with
condensed chromatin. F. N-AChE-S-inducible apoptosis is dose-dependent. Percent of apoptotic U87MG cells under transient transfection with
increasing plasmid doses. (*p=0.03, **p=0.002 Student’s t test). G. Effects of stable transfection on cell viability. CHO cells were co-transfected with
either N-AChE-S or AChE-S vectors, and the G-418 antibiotic resistance plasmid, and were grown for 14 days in the presence of G-418. Individual
surviving clones were isolated and expanded and cellular AChE activity was measured (p=0.02, Student’s t-test). Note that individual clones
transfected with N-AChE-S all showed considerably lower activity, largely below the average activity in human brain extracts (dashed line).
doi:10.1371/journal.pone.0003108.g002
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cell death (see below), suggesting a caspase-mediated apoptotic
cascade [14]. Highlighting the specificity of the N-AChE-S-
induced effects, caspase 3 levels were inversely reduced in N-
AChE-R-transfected cells (Fig 2B).Therefore, the N-terminal
extension by itself appeared to be insufficient to cause the cell
death conferred by N-AChE-S.
To directly estimate the efficiency and dynamics of the N-AChE-
S-induced cell death, we selected 3T3 cells for microinjecting N-
AChE-S. Co-injection of a cleavable caspase-activated GFP
reporter, equipped with a nuclear localization signal which enables
translocation to the nucleus in the presence of activated caspases
(Fig 2C, scheme) served for follow-up of the induced changes. The
caspase reporter and an ‘‘empty’’ vector were microinjected for
control (Fig 2D,E). Within 24 hrs, injection of the caspase reporter
alone induced cytoplasmic GFP fluorescence in 9463% of the cells
(Fig2D).Incontrast,8563%oftheN-AChE-Sinjected cellsshowed
nuclear GFP fluorescence, reflecting caspase activation, and
acquired condensed nuclei characteristic of apoptosis (Fig 2D,E).
In cells transiently transfected with .1.2 ng/cell of the N-
AChE-S DNA, N-AChE-S induced dose-dependent apoptosis
(Fig 2F). Next, individual clones of CHO cells, which do not
express any endogenous AChE variant were stably transfected
with N-AChE-S or the shorter AChE-S, for comparison. Cloned
cells presented considerably less N-AChE-S protein than clones
stably transfected with AChE-S (also called ‘‘tailed’’ [15]). This
was reflected in considerably lower ACh hydrolytic activity than
that of cells stably transfected with AChE-S (1068.4 vs.
150645 nmol substrate hydrolyzed/min/mg protein, Fig 2G,
dashed line). Such low activities, lower than the average activity
observed in the human brain, indicated a possible selective
pressure against expression of N-AChE-S in high levels. Thus,
microinjection as well as transient and stable transfections all
suggested that excess N-AChE-S is incompatible with cell viability.
N-AChE-S displays similar catalytic characteristics to other
AChE variants
Fractionation and activity tests demonstrated that AChE-S and
N-AChE-S largely remained within the cells, whereas AChE-R
and N-AChE-R both showed a tendency to be secreted, (Fig
S1A).Sequence analysis predicted that while the AChE signal
peptide is likely masked by the N-extended terminus, the new N-
AChE variants include an additional signal peptide. Higher
expression levels for the shorter variants were observed by
immunoblot analysis of transiently transfected cells. Enzymatic
Activity (with acetyl-thiocholine) staining of native gels showed
matched differences in enzyme activity (Fig S1B), indicating
proportional expression and activity of the various AChE proteins.
Nevertheless, the key enzymatic characteristics (e.g. Km, substrate
inhibition) were indistinguishable for N-AChE-S and N-AChE-R
as compared with the shorter variants (Fig S1C,D), indicating that
the N-extended variants are correctly folded. Thus, N-AChE-S
was found to be expressed at lower levels than the shorter variants,
but despite this, it was the only variant with an apoptogenic effect.
N-ACHE-S promotes GSK3 activation and Tau hyper-
phosphorylation
The relatively low levels of N-AChE-S could potentially be due
to misfolded proteins activating ER stress-induced apoptosis. To
test this possibility, we measured the levels of the ER stress markers
GRP78 and Xbp. Both GRP78 levels and the ratio between
spliced and unspliced variants of Xbp were similar to those of cells
transfected with the other variants or control cells (Fig S2A,B),
suggesting that the observed apoptogenic effects were not caused
by the misfolded protein response or the ACh hydrolytic
properties of N-AChE-S. Nevertheless, high levels of N-AChE-S
could signal the cell of a ‘‘possible threat’’, inducing another kind
of cellular stress, compatible with other cases where an
overexpressed protein can lead to cell death, e.g. hIAPP in B
cells[16]. Next, we explored relevance to the observed apoptosis of
the Tau kinase GSK3, which regulates apoptosis-modulating Bcl
proteins including Bax [17,18] and was implicated in Alzheimer’s
disease pathology [19]. We tested the potential involvement of
GSK3 in N-AChE-S-induced apoptosis in U87MG cells, which are
more readily amenable for transfection than primary neurons.
Supporting such involvement, N-AChE-S expression selectively
decreased the levels of inactive GSK3 carrying phosphorylated
serine, whereas total GSK3b and the levels of hyper-activated
GSK3a and b with phosphorylated tyrosine remained unchanged
(Fig 3A). Thus, larger GSK3 fractions were active under N-AChE-S
expression. Moreover, N-ACHE-S overexpression induced progres-
sive increases in the hyper-phosphorylation of Tau in cultured
U87MG cells, reaching a 37% increase by 48 hr post-transfection
(P,0.05, Fig 3B). Correspondingly, U87MG cells transfected with
N-AChE-Sshowed25%enhanced immunolabelingofactivated Bax
(Fig 3C), susceptible to blockade by the GSK3 inhibitor SB316763,
known to suppress cell death [18]. Importantly, SB316763 reduced
the immunolabeling of both activated Bax and hyper-phosphorylat-
ed Tau in cultured cells by about 20% as compared to N-AChE-S
transfected cells with no inhibitors (Fig 3D and data not shown).
Also, SB316763 largely prevented the N-AChE-S apoptotic effect, to
a similar extent as caspase inhibition, and without affecting AChE’s
catalytic activity (Fig 3D,E).
Bcl proteins mitigate the N-AChE-S induced apoptosis
Since AChE silencing was shown to prevent apoptosome
formation [9], we tested if the N-AChE-S effect occurs upstream
to the mitochondrial membrane permeablization, characteristic of
apoptosis. Cultured cells were co-transfected with N-AChE-S and
the anti-apoptotic protein Bcl-2 or its family members, Bcl-xL and
BI. All of these proteins disable Bax from triggering the
permeabilization of mitochondrial membranes, and all suppressed
the N-AChE-S-induced cell death (Fig 3F), compatible with the
notion of a ‘‘classical’’ apoptotic pathway.
Cell surface N-AChE-S location
We considered the possibility that in the N-extended AChE
variants, the retained original signal peptide can be used as
transmembranal domain similar to the homologous protein
neuroligin [20]. To address this issue, we labeled Fasciculin-2,
an AChE inhibitor which is impermeable to the cell membrane,
with tetramethyl-rodhamine (Fas2*)[21]. 293HEK cells which do
not express endogenous AChE were co-transfected with N-AChE-
S and GFP for 18 hrs and were exposed to Fas2*. Live imaging
was performed before Fas2* addition, and every 5 minutes after its
addition. Cells co-transfected with GFP+N-AChE-S but not non-
transfected neighbor cells showed vesicular internalization of
Fas2*(Fig 4A,B). We than performed the same experiment and
fixed cells after 0,5,15 or 30 minutes. Fixation disrupted the
vesicles; however, red labeling reflecting internalized Fas2*
remained in the cytoplasm of cells expressing GFP+N-AChE-S
compared to control cells (Fig 4C,D). Labeling peaked after
5 minutes from Fas2* addition, remained unchanged after
15 minutes and declined after 30 minutes. Our results indicate
that N-AChE-S is positioned in the membrane with the catalytic
domain towards the extracellular space, allowing Fas2* binding. In
addition, we used antibodies specific for the extended N-terminus
N-AChE-S in Alzheimer’s Brain
PLoS ONE | www.plosone.org 4 September 2008 | Volume 3 | Issue 9 | e3108Figure 3. N-AChE-S induces suppressible GSK3-activation, Tau hyper-phosphorylation and Bax activation. A. Immunoblots. N-AChE-S
reduces serine-phosphorylated P-GSK3 while maintaining unchanged total GSK3b and tyrosine phosophorylated GSK3, and elevating active-Bax. B.
Tau hyper-phoshorylation: N-AChE-S, but neither AChE-S nor N-AChE-R induces progressive increases in hyper-phosphorylated Tau (Tau AT8). Alpha
tubulin 4 served as reference. C. N-AChE-S-inducible GSK3 dephosphorylation facilitates Bax activation. Shown are micrographs of N-AChE-S
transfected cells with elevated phosphorylated Bax labeling compared to U87MG control (Ctrl) cells. GSK3 inhibition suppresses this labeling.
Quantification: % increase in Bax labeling of NS overexpressing cells, preventable under GSK-I (SB316763) treatment (**p=0.00009 Student’s t test).
D. GSK3 and Caspase inhibition suppress N-AChE-S-induced apoptosis. % TUNEL labeling of N-AChE-S transfected cells. Note that 5 mM SB316763
(GSK3-I) and 80 mM Z-VAD-FMK (caspase-I) reduced apoptosis. (GSK-I p=0.000013, Casp3-I p=9610
211 Student’s t test). E. GSK3 and Caspase
inhibitors do not affect AChE catalytic activity. F. Bcl proteins suppress N-AChE-S-induced apoptosis: U87MG cells co-transfected with N-AChE-S and
Bcl-2 (# p=0.00001), BI (*p=0.03), or Bcl-XL (p=0.054 Student’s t test) showed variably suppressed TUNEL labeling.
doi:10.1371/journal.pone.0003108.g003
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PLoS ONE | www.plosone.org 5 September 2008 | Volume 3 | Issue 9 | e3108Figure 4. N-AChE-S Membranal localization and Fasciculin-2 Internalization. A. Fasciculin-2 internalization. Tetramethylrodhamine labeled
Fasciculin2 was added to the medium of 293 cells co-transfected with N-AChE-S and GFP. Shown is internalization of labeled Fasciculin 2 yielding
fluorescence into N-AChE-S transfected, but not non-transfected cells at 15 and 30 minutes. Pictures were taken by live imaging. B. Schematic
representation of N-AChE-S in the cell membrane and its internalization. C. Tetramethylrodhamine labeled Fasciculin2 was add to the medium of N-
AChE-S and GFP co-transfected 293 cells were fixed after: 0,5,15 and 30 min. The density of Fasciculin2 was measured. Columns show density in N-
AChE-S transfected vs non-transfected cells at the noted times (*p.0.05, **p.0.005 Student’s t test). D. Representative pictures of the experiment
quantifies in C.1.Merge picture (yellow fluorescence notes Fasciculin2 internalization into GFP-expressing cells). 2. Co-transfected GFP and N-AChE-S
cells. 3. Fasciculin-2 internalized 4.Light picture.
doi:10.1371/journal.pone.0003108.g004
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label N-AChE-S in transfected U87MG cells. An ‘‘empty’’ vector
served as control (Fig S3A, scheme). In transmission electron
microscopy, N-ACHE-S-transfected cells yielded generally similar
labeling patterns with the N-specific and core domain antibodies,
peaking up to 6 nm from the cellular membrane (Fig S3A,B).
Apart from the membrane-associated labeling, a total of 11% of
the gold beads adhered to endocytotic vesicles (identified by their
clathrin-coated contours [23], compatible with the Fas2* data.
Core domain contributions to N-AChE-S-induced
apoptosis
At the extracellular domain of synaptic membranes, neurexin
interactions with neuroligin transduce intracellular signals through
synaptic protein partners [20]. In view of our Fas2* and electron
microscopy results, we speculated that the intracellular N-terminus
of N-AChE-S might similarly mediate intracellular signaling in
response to extracellular cues. Given that inhibitor interactions
induce structural changes in the AChE core domain [24], we
assessed the capacity of the carbamate active site inhibitor,
pyridostigmine, the peripheral site inhibitor of AChE, propidium
or the quaternary AChE inhibitor, BW284C51, known to be
impermeable to the cell membrane [25] to affect N-AChE-S-
induced apoptosis. All of these agents reduced apoptosis in N-
AChE-S-transfected cells to the levels observed in N-AChE-R
transfected or control cells (Fig 5A). These findings demonstrated
inherent involvement of the core domain of AChE, where the
active site is embedded, in the N-AChE-S-induced apoptotic
process. The simplest explanation for the mechanism(s) involved
therefore suggests that the N-AChE-S-induced apoptosis may
initiate extracellularly, as it is susceptible for suppression by small
molecule inhibitors excluded from cellular entrance (e.g.
BW284C51) and since such inhibitors appear to prevent the
transduction of the signal into the cell.
Since N-AChE-S is enzymatically active, we further wished to
test the possibility that cells were dying because of the lack of ACh.
Addition of the non-degradable ACh-analog carbachol did not
change the observed cell death (Fig 5B), excluding this option and
suggesting structural, rather than enzymatic involvement of the
core domain in the induced cell death.
Insult stimuli facilitate inherent N-AChE-S expression and
apoptosis
Notably, various cellular and organismal stimuli induce AChE
overexpression, alternative splicing and alternate promoter choices
[13,26,27]. Therefore, we tested the effects of stressors-induced
gain of N-AChE-S function on apoptosis outcome. Carbachol
(10 mM), ß–mercaptoethanol, a reducing agent which denatures
proteins by reducing disulfide bonds (0.2 M), or thapsigargin,
which releases calcium from the ER and intracellular stores
(10 mM) [28] all induced significant inherent overexpression of the
hE1e exon encoding the extended N-terminus in U87MG cells
(median test p,0.03). In contrast, glutamate, the NMDA receptor
agonist (0.5 mM), and cortisol, a glucocorticoid hormone
protecting nerve cells from acute stress responses (0.5 mM) [29]
showed no effect on hE1e expression (Fig 5C). This called for
testing the consequences of loss of N-AChE-S function on
apoptosis. In cells co-transfected with N-AChE-S and an AChE-
targeted siRNA, loss of N-AChE-S expression selectively abolished
its apoptotic effect. siRNA also ameliorated the cell death induced
by thapsigargin; in comparison, suppressed N-AChE-R expression
or cortisol treatment had no effect (Fig 5D,E). Thus, inherent gain
of N-AChE-S function induced apoptosis, whereas loss of its
function suppressed it. Together, these data identified N-AChE-S
as an upstream apoptotic trigger encompassing most of the
‘‘classical’’ cell death elements (Fig 5F) and likely acting through
the interaction of yet unknown intracellular element(s) with the N-
terminal extended domain.
N-AChE-S expression in AD
Last, but not least, we turned to the AD brain. When protein
from cortical tissues was differentially extracted in detergent and
salt-containing solutions, AD cortices predictably showed reduced
AChE activity as compared to matched non-demented controls
(NDC). Reduction was observed in the membrane-associated
fraction (where AChE-S is present [30]) (Fig 6A). Neither the
soluble nor the membrane protein fractions showed such
decreases, indicating that the reduction was primarily of AChE-
S, likely due to the massive loss of cholinergic neurons. In NDC
cortices, quantitative real-time RT-PCR calibrated using each
cDNA clone showed that transcripts spanning the hE1e exon
which encodes the N-terminal extension represent approximately
6% of total AChE mRNA (4000 transcripts per ng RNA,
compared to 55,700 transcripts of total AChE mRNA per ng).
Parallel tests showed that both the core domain and the major
exon 6 decreased by 40+/226% in AD as compared with NDC
cortical tissues (Fig 6B, and data not shown). Therefore, AD tissues
contained less AChE-S (which normally constitutes 90% of the
enzyme) but similar amounts as NDC of N- AChE and AChE-R
(each constituting about 6% of AChE mRNA transcripts).
Our mRNA analyses suggested that in the remaining cholin-
ergic neurons N- AChE-S constitutes a larger part of AChE than
in NDC brains. To challenge this hypothesis, we used quantified
FISH analysis which indeed identified 273% enhanced hE1e
expression in AD cortical cells with neuronal morphology as
compared with NDC sections (Median test p=0.03) (Fig 6C).
Immuno-labeling further demonstrated 152% elevated levels of
the N-terminus characteristic of N-AChE-S in AD compared to
NDC cortices (Median Test p=0.03) (Fig 6D), together suggesting
AD-associated overexpression of N-AChE-S in cortical neurons.
Association with hyper-phosphorylated Tau in AD
Tau hyper-phosphorylation is a marker of AD pathology that is
directly related to cell death. Importantly, N-AChE and AChE-S
showed similar patterns of expression to that of hyper-phosphor-
ylated Tau in the AD cortices. The majority (72, 70 and 77% of
measured cells out of approximately 100 in each group) of cells
expressing N-AChE, AChE-S or hyper-phosphorylated Tau were
7–24 mm in length, compatible with the size of interneurons
(Fig 6E). Moreover, the labeling intensity of N-AChE, and to a
somewhat smaller extent also of AChE-S (probably because only
part of the AChE-S molecules are N-AChE-S) were directly
correlated with that of hyper-phosphorylated Tau (Fig 6F).
Together with the cell studies, these observations are compatible
with the hypothesis that N-AChE-S overexpression in AD cortical
neurons is causally linked with the apoptotic destiny reported for
neurons expressing hyper-phosphorylated Tau.
Discussion
Recent reports of AChE association with apoptosis [9,10] left
unexplained the long-term survival of AChE-expressing choliner-
gic neurons. Our current findings provide an unequivocal answer
to this question by pointing at N-AChE-S as the only apoptotic
AChE variant. We further demonstrate that N-AChE-S induces
cell death only when present above a critical threshold. To explore
the molecular mechanism(s) underlying this apoptotic role, and to
N-AChE-S in Alzheimer’s Brain
PLoS ONE | www.plosone.org 7 September 2008 | Volume 3 | Issue 9 | e3108Figure 5. N-AChE-S and Thapsigargin induced apoptosis are suppressed by AChE-I and siRNA. A. Small molecule-mediated suppression
of N-AChE-S-induced apoptosis: Normalized TUNEL labeling. Inset drawing: Pyridostigmine (Pyr), propidium (Pro), or BW284C51 (BW) are variably
targeted AChE-Is. Columns: All AChE-Is prevented cell death in N-AChE-S but not N-AChE-R-transfected cells (NS vs. NR p=0.00002, NS vs. NS+Pyr
0.008, NS vs. NS+BW p=0.000001, NS vs. NS+Pro p=0.000002 Student’s t test) B. Carbachol fails to prevent N-AChE-S-induced cell death. Carbachol
addition did not affect cell death in control, N-AChE-R or N-AChE-S (Blue Script, BS is used as empty vector) transfected cells. C. Apoptotic stimuli
induce hE1e over-expression. QRT-PCR of U87MG cells subjected to the noted agents. Columns: fold change of hE1e levels over naive cells (Thapsi
*p=0.03, Carb p=0.03, ß-me p=0.02 Median test n=4). D. AChE-targeted siRNA suppression. AChE targeted siRNA but not a control siRNA reduced
AChE activity in cells transfected with either N-AChE-S or N-AChE-R, (NR ctrl vs NR siRNA p=0.002; NS ctrl vs NS siRNA p=0.002; n=3 different
experiments, Median test). E. siRNA suppression of N-AChE-S-induced apoptosis. Apoptosis was effectively suppressed in cells co-transfected with N-
AChE-S and siRNA, or cells treated with Thapsigargin, but siRNA did not affect cortisol-treated or N-AChE-R transfected cells. (NS ctrl vs. NS siRNA
p=0.00009, NS vs. NR p=0.00002, thapsi ctrl vs. thapsi siRNA p=0.00001, thapsi vs. ctrl p=3
27 thapsi siRNA vs. crtl siRNA p=0.033, Student’s t test).
F. The N-AChE-S apoptotic cascade. NS upregulation by apoptotic insults co-activates GSK3 by serine dephosphorylation, facilitating activation of Bax
and caspases, yielding apoptosis preventable by Bcl-2 proteins or GSK3, AChE, and caspase inhibitors.
doi:10.1371/journal.pone.0003108.g005
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PLoS ONE | www.plosone.org 8 September 2008 | Volume 3 | Issue 9 | e3108Figure 6. N-AChE-S overexpression in AD cortical neurons associates with Tau hyper-phosphorylation. A. Differential fractionation of
AChE hydrolytic activity. Cortical protein was fractionated into low salt (LS, soluble protein), low salt detergent (LSD, membrane-associated) and high
salt (HS, integral membrane and nuclear proteins) and AChE activity was measured. Note decrease in LSD (AChE-S-enriched) fraction, but not LS or HS
fractions (p=0.0476, n=4 NDC, 8AD, Median test). B. AD-associated changes in AChE mRNA transcripts. Columns: QRT-PCR. Note AD-associated
decrease as compared to NDC samples in the S, but not the N or R encoding exons. (p=0.055, n=10 AD, 5 NDC Wilcoxon Two Sample Test). C. Inset
is: E1e labeling of post mortem sections from human entorhinal cortex. Columns are quantification of labeling density per area. (Median test,
*p=0.0286, n=4 in each group). D. N-AChE-S Immunostaining in AD and NDC cortices. Columns are quantification of density per area (*p=0.029
n=5 NDC, 9AD Median Test). E. AD Entorhinal cortices immunolabeled for N-AChE, AChE-S or hyper-phosphorylated Tau-P. F. N-AChE and AChE-S
labeling correlate with Tau-P density. Tau-P, N-AChE, and AChE-S labeling were quantified using immunohistochemistry on sections from the
entorhinal cortex of AD patients. (Pearson’s correlation for N-AChE and Tau-P, 0.73, p=0.03).
doi:10.1371/journal.pone.0003108.g006
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neurons, we systematically manipulated N-AChE-S expression in
cell culture experiments, and demonstrated that gain of N-AChE-
S function invariably induces apoptosis whereas loss of its function
improves survival.
Enforced N-AChE-S overexpression induced apoptosis both in
primary cortical cells and in different cell lines of various tissue and
organismal origins. This attributes to this protein a conserved and
ubiquitous role as a general trigger of apoptosis. In the AD cortex,
neuronal loss reaches 30–90% [31] in a manner attributable to the
formation of hyper-phosphorylated Tau and neurofibrillary
tangles [1]. Circulation AChE levels are elevated during normal
aging [32]; moreover, the ApoE4 genotype [33], mutations in
presenilins [34] and the presence of Aß [35–37] all induced
upregulation of AChE activity. AChE upregulation was also
reported as being induced by the apoptotic JNK pathway [38], as
well as by damaging light in retinal neurons [39]. Here we report
that acute cellular stress reactions and calcium misregulation, both
implicated in AD and in the susceptibility to cell death [40], lead
to N-AChE-S overexpression. Our current findings thus indicate
that the protein involved in all the above phenomena was likely the
N-ACHE-S variant. Further studies will be required to explore the
possible function(s) of N-AChE-S in normal tissues, and define if it
is involved, for example in the programmed cell death character-
istic of developing neurons [41].
The N-AChE-S, but not the N-AChE-R or the shorter AChE-S
variants induced cell death, suggesting that both the N- and the-S
termini are required for this process. Additionally, various AChE
inhibitors suppressed the N-AChE-S induced apoptosis pointing at
the central core domain, where AChE’s active site is embedded
[42] as being causally involved as well. The most likely explanation
for this multi-domain involvement is that structural, rather than
enzymatic features of N-AChE-S protein are involved. We
localized part of the N-AChE-S variant to the cell membrane
and demonstrated extracellular inhibitor interactions and rapid
internalization for this protein, suggesting that the extended N-
terminus of N-AChE-S protrudes intracellularly, similar to the
homologous protein neuroligin [20]. Inhibitor interactions were
shown by others to exert structural changes on the AChE molecule
[43], indicating parallel changes in N-AChE-S. That various
AChE inhibitors attenuate the N-AChE-S-induced apoptotic
outcome therefore suggests that, the core domain transduces
signals to the cell through the cytoplasmic N-terminal domain.
Together, this implies that N-AChE-S likely operates as a
bifunctional entity having properties characteristic of both
enzymes and ligand-activated receptors. Considering the above
arguments, these findings may also explain the reported disease-
modifying effects of anticholinesterases [4,5] and can possibly
outline testing their future use as prophylactic agents.
Our current finding of increased N-AChE expression in AD
cortices, which lose 30–50% of their core AChE expression and
activity, is compatible with the enhanced apoptosis in these tissues.
Supporting the notion of causal relationship with this process, both
cellular stress and calcium imbalances have been implicated in
GSK3 activation and in cell death in the AD brain [12] through
hyper-phosphorylated Tau, presenilin, APP and Bax [18]. The N-
ACHE-S-induced dephosphorylation of the Ser residue activating
GSK3 kinase properties corroborates this association. Others
reported increased Bax levels and TUNEL staining in neurons
with Tau hyper-phosphorylation. A recent report, however, argues
that Tau hyper-phosphorylation is protective [44]. Our findings
did not distinguish between these possibilities but demonstrate
apparent association of Tau hyper-phosphorylation with the N-
AChE-S apoptotic mechanism. We further predict that exposure
to apoptotic stressors would likely induce N-AChE-S expression,
particularly in the cholinergic neurons with higher basal AChE
expression, and cause apoptotic cell death. At least part of the
currently employed AD therapeutics may ameliorate the effect of
this overexpression by preventing the N-AChE-S-induced apo-
ptosis, thus delaying disease progression [4,5]. Further delineation
of this induction and ways to manipulate it for preventing the
premature death of cholinergic neurons at earlier stages of the
disease would therefore merit special attention.
Materials and Methods
Human brain tissue
Brain tissue from AD patients (n=10) and matched non-
demented controls (n=5) was obtained from The Netherlands
Brain Bank. Ethical approval and written informed consent from
the donors or the next of kin was obtained in all cases.
Neuropathological Braak staging of neurofibrillary changes (I–
VI) was performed post mortem (Table S2).
Primary cortical cell culture
Cerebral cortex was separated from the brain of 15
th day embryos
ofFVB/N mice, minced,and cells plated on poly-L-ornithinecoated
cover slips in Neurobasal medium, B27 supplement, Glutamax and
Penicillin/streptomycin (Invitrogen). Transfections were performed
with lipofectamine 2000 (Invitrogen).
Plasmids
The N-AChE-R and N-AChE-S plasmids are modifications of
CMV-AChE-S and CMV AChE-R with the hE1e exon inserted
in the HindIII cloning sites. Bax Inhibitor Plasmid (BI) was from
Science Reagents El Cajon, CA, and the caspase detector was
from Clontech (Palo Alto, CA).
Microinjection
NIH 3T3 cells were microinjected using an Axiovert200M Zeiss
microscope equipped with a microinjection system, incubated for
24 hours and then viewed. This involved an MRC-1024 BioRad
confocal scanhead coupled to a Zeiss Axiovert 135M inverted
microscope with a 406/NA=1.3 oil immersion objective. GFP
was detected at 488 nM the excitation wavelength and a
HQ525620 filter served for collecting emission.
Statistics Methods
Student’s t-test was used in cell culture experiments, where
cell numbers were large enough to assume normal distribution.
Median test is a-parametric test was used for comparing the
median value of two different populations that were relatively
small, assuming abnormal distribution (minimum 4 samples,
maximum 10 e.g. mRNA transcripts, protein densities and protein
activity) as compared to control.
The Wilcoxon test was preferred over the median test when
one or more observations were ‘‘off scale’’. It served for calibrating
cDNA transcripts from AD and control samples.
Pearson correlation test describing the strength of an
association between variables was used to measure the correlation
between N-AChE-S and hyper-phosphorylated Tau. The aim was
to test if linear relationship exists between these values of variables.
Image analysis
Immunohistochemistry and In situ hybridization experiments
were quantified by the ImageJ 1.33 free software (http://rsb.info.
nih.gov/ij/).
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selected: Mean gray value (which measures the density of the
selected pixels divided by the number of pixels), to quantify
staining intensity.
2. We used the ‘‘freehand selection’’ tool to draw a line around
a single cell we wanted to measure and then selected an
appropriate measure in the ‘‘analyzis’’ tool; in all cases, we
analyzed many cells (20–30) in each picture. We selected 2–3
empty spots in the tissue to determine the background for each
picture, and subtracted it from each of the values observed for the
measured cells to normalize light efficiency differences that could
occur between different pictures.
3. The total average for a single experiment was composed of 4
different pictures at least. Standard deviation values were
calculated for these averages, to challenge the possibility that a
specific change was an outlier which occurred outside the normal
range calculated for the other pictures.
The averages of the different groups were used and are depicted
in the figures.
4. Data collected from the different cells in each picture was
used to derive an average value for that picture. In case of cell
culture experiments, 5–8 different pictures were used to assess
each treatment and were analyzed as noted before.
5. For Western Blot analysis we used the ImageJ Gel Analyzer
option, inwhich wemarked a rectangular shape for eachbandinthe
gel. We captured the graph view of the intensity as area of the band,
which should correlate with the quantity of protein detected, and
used the areas measured as reflecting protein quantity. Normaliza-
tion involved dividing the area by that obtained for tubulin 4 from
that sample,, which served as the housekeeping standard.
Supplementary methods
Immunohistochemistry, confocal and electron microscopy, fluo-
rescent in situ hybridization (FISH), cell cultures, siRNA design and
production and AChE activity tests were as described [45] (and/or
are all detailed under Supplementary Methods (Text S1).
Real Time PCR, TUNEL Apoptosis assay, immunocytochem-
istry, protein extraction were as described [46] (Text S1, Table S3
antibodies list and Table S4 probes list).
Supporting Information
Text S1 Supplementary Materials and Methods.
Found at: doi:10.1371/journal.pone.0003108.s001 (0.05 MB
DOC)
Figure S1 N-AChE-S characteristics. A. Cellular and secreted
AChE forms. Hydrolytic activity of the AChE variants in
transiently transfected U87MG cell extracts and medium. Note
that AChE-R and N-AChE-R are largely secreted, whereas
AChE-S and N-AChE-S are largely cellular. B. Immunoblot and
activity staining. Top: Immunoblot. Note low-level expression of
N-AChE-S and N-AChE-R compared to the corresponding
shorter counterparts. Bottom: Activity staining in a native gel.
Note migration and staining intensity differences. C. Km analysis.
Percentage of maximal acetylthiocholine (ATCh) hydrolytic
activity as a function of substrate concentration. Note indistin-
guishable Km values (0.3360.092, 0.2960.035, 0.3560.13, and
0.3960.17) and similar Hill’s coefficients (0.9460.12, 0.8560.05,
0.9160.17, 0.8760.18) for the AChE-R, AChE-S, N-AChE-R
and N-AChE-S variants, respectively. D. Substrate inhibition. All
variants showed inhibition under acetylthiocholine (ATCh)
concentrations .5 mM.
Found at: doi:10.1371/journal.pone.0003108.s002 (1.42 MB TIF)
Figure S2 N-AChE-S Sustained Unfolded protein Response
under Transfection. A. GRP78 levels: Immunoblot shows similar
levels of GRP78, an unfolded protein response marker, in cells co-
transfected with AChE-S, N-AChE-R and N-AChE-S. B. XBP
splicing ratios: 3% Agarose gel shows the PCR products of XBP
transcripts, the upper band is the unspliced form, and the lower
band is the spliced form. N-AChE-S transfection sustained a
similar ratios between unspliced/spliced forms to those seen with
the other AChE variants. Thapsigargin induced ER stress (below)
showed higher expression of XBP and a higher ratio for the spliced
form (columns).
Found at: doi:10.1371/journal.pone.0003108.s003 (1.30 MB TIF)
Figure S3 Membranal localization of N-AChE-S. Top Scheme:
Antibodies to the N-terminus or core domain of N-AChE-S (NS).
SP: Original signal peptide. A. Electron micrographs: Gold beads-
decorated antibodies labeling of U87MG cells transfected with N-
AChE-S. Note labeling close to the plasma membrane or within
endocytotic, clathrin-coated vesicles (arrows). B. Labeling distri-
bution. Columns: Distance of gold beads from the plasma
membrane. 11% of intracellular N-AChE-S labeling for both the
N-terminus and the core domain occurred close to the plasma
membrane, another 11% - in endocytotic vesicles.
Found at: doi:10.1371/journal.pone.0003108.s004 (1.86 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0003108.s005 (0.07 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0003108.s006 (0.04 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0003108.s007 (0.04 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0003108.s008 (0.03 MB
DOC)
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